The aim of the TRANSITION study was to evaluate tolerability and assess the ideal time for initiating treatment with Entresto (sacubitril/valsartan) in patients stabilised after acute decompensated heart failure (ADHF). The results support that initiation of Entresto is equally tolerable in these patients, if initiated either in hospital or shortly after discharge.¹